Cases from the Community: Clinical Investigators Provide Perspectives on Actual Patients with Pancreatic Cancer


 
Track 1: Case: A 66-year-old man with borderline-resectable pancreatic cancer undergoes R0 resection after receiving neoadjuvant FOLFIRINOX
Track 2: Role of vascular resection for patients with borderline-resectable pancreatic cancer
Track 3: Case: An 89-year-old man with resectable pancreatic cancer declines surgery and receives a modified dose of gemcitabine/nab paclitaxel followed by stereotactic body radiation therapy
Track 4: Selection of neoadjuvant and adjuvant therapy for patients with resectable pancreatic cancer
Track 5: Perspective on the use of adjuvant therapy for patients who have received neoadjuvant therapy
Track 6: Case: A 56-year-old man presents with malignant ascites 1 month after receiving therapy for locally advanced, unresectable pancreatic cancer
Track 7: Case: A 46-year-old woman who presents with abdominal pain is diagnosed with pancreatic cancer and a single liver metastasis and receives FOLFIRINOX followed by surgical resection
Track 8: Case: An 80-year-old woman with pancreatic cancer and liver oligometastases receives gemcitabine/nab paclitaxel and radiofrequency ablation
Track 9: Selection of first-line therapy for metastatic disease based on patient age and performance status
Track 10: Case: A patient develops miliary tuberculosis after chemotherapy for pancreatic cancer
Track 11: Case: A 66-year-old woman receives nal-IRI (nanoliposomal irinotecan)/5-FU/leucovorin as second-line therapy for metastatic pancreatic cancer and experiences neutropenia
Track 12: Case: A 74-year-old woman with metastatic pancreatic cancer receives FOLFIRINOX but has to discontinue oxaliplatin after 3 months because of neuropathy
Track 13: Therapeutic options for patients with metastatic pancreatic cancer in the third-line setting
Track 14: Perspective on the use of drug holidays for patients with metastatic pancreatic cancer; approach to maintenance therapy
Track 15: Assessment of BRCA mutation and microsatellite instability status in patients with pancreatic cancer
Track 16: Case: A 71-year-old woman with metastatic pancreatic cancer and a BRCA1 germline mutation receives FOLFIRINOX followed by maintenance olaparib on the POLO trial
Track 17: Screening patients with BRCA mutations for pancreatic cancer
Track 18: Case: A 51-year-old man with metastatic pancreatic cancer and multiple comorbidities achieves a good clinical response to off-label pembrolizumab
Track 19: Efficacy of the pegylated human hyaluronidase enzyme PEGPH20 for patients with advanced pancreatic cancer and high levels of hyaluronan
Track 20: Therapeutic approach to metastatic pancreatic cancer in elderly patients with BRCA mutations
Track 21: Molecular profiling for patients with pancreatic cancer
 
FACULTY
 
Andrew E Hendifar, MD
Medical Director
Pancreatic Cancer
Gastrointestinal and Neuroendocrine Malignancies
Cedars-Sinai Medical Center
Los Angeles, California
 
Eileen M O’Reilly, MD
Winthrop Rockefeller
Chair in Medical Oncology
Section Head Hepatopancreaticobiliary/
Neuroendocrine Cancers
Gastrointestinal Oncology Service
Associate Director
David M Rubenstein Center for Pancreatic Cancer
Attending Physician, Member
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, New York
 
Philip  A  Philip, MD, PhD
Kathryn Cramer Endowed Chair
in Cancer Research
Professor of Oncology and Pharmacology
Leader
GI and Neuroendocrine Oncology
Vice President of Medical Affairs
Karmanos Cancer Institute
Wayne State University
Detroit, Michigan
 
Margaret A Tempero, MD
Director
UCSF Pancreas Center
The Rombauer Family Distinguished Professorship in Pancreas Cancer
Clinical and Translational Science
Leader
Pancreas Cancer Program
Professor of Medicine, Division of Hematology and Oncology
University of California, San Francisco
San Francisco, California
 
MODERATOR
 
Neil Love, MD
Research To Practice
Miami, Florida